Dyne Therapeutics GAAP EPS of -$0.73 beats by $0.04

* Dyne Therapeutics press release [https://seekingalpha.com/pr/20508820-dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights] (DYN [https://seekingalpha.com/symbol/DYN]): Q1 GAAP EPS of -$0.73 beats by $0.04.
* Cash, cash equivalents and marketable securities were $972.2 million as of March 31, 2026. The Company continues to expect that its cash, cash equivalents and marketable securities as of March 31, 2026, will be sufficient to fund its operations into the first quarter of 2028.

MORE ON DYNE THERAPEUTICS

* Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript [https://seekingalpha.com/article/4880203-dyne-therapeutics-inc-dyn-presents-at-td-cowen-46th-annual-health-care-conference-prepared]
* Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case [https://seekingalpha.com/article/4880133-dyne-therapeutics-strong-deliver-data-strengthens-the-bull-case]
* Dyne Therapeutics GAAP EPS of -$0.76 beats by $0.02 [https://seekingalpha.com/news/4559273-dyne-therapeutics-gaap-eps-of-0_76-beats-by-0_02]
* Seeking Alpha’s Quant Rating on Dyne Therapeutics [https://seekingalpha.com/symbol/DYN/ratings/quant-ratings]
* Historical earnings data for Dyne Therapeutics [https://seekingalpha.com/symbol/DYN/earnings]